Recent clinical trials have demonstrated that programmed death ligand 1 (PD-L1) or programmed death 1 (PD-1) blockade exhibit clinically meaningful anti-tumor activity together with an acceptable safety profile when used in the treatment of HNSCC patients (5, 6). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.